We studied a multicenter cohort of 310 patients with laboratory-confirmed COVID-19, who were consecutively hospitalized at four sites in Whenzou, Zhejiang Province (China), between January and February 2020. These patients have been included in a prior study examining the relationship between MAFLD with increased non-invasive fibrosis scores and risk of COVID-19 severity [5]. Patients with viral hepatitis, excessive alcohol consumption, active cancers or chronic pulmonary diseases were excluded. Clinical and laboratory data were collected in all patients at hospital admission, including NLR that was calculated by dividing the absolute number of neutrophils by the absolute number of lymphocytes. Obesity was diagnosed as body mass index >25 kg/m2. Pre-existing diabetes was defined as self-reported history of disease or use of glucose-lowering medications. All patients were screened for hepatic steatosis by computed tomography and subsequently diagnosed as MAFLD, according to the recently proposed diagnostic criteria [2]. The severity of COVID-19 was assessed during hospitalization and classified as severe and non-severe based on the current management guideline [6]. The study protocol was approved by the local ethics committees of the four hospitals. The requirement for written informed consent was waived due to the retrospective and anonymous nature of the study design.

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19

Targher, G
;
Mantovani, A;
2020-01-01

Abstract

We studied a multicenter cohort of 310 patients with laboratory-confirmed COVID-19, who were consecutively hospitalized at four sites in Whenzou, Zhejiang Province (China), between January and February 2020. These patients have been included in a prior study examining the relationship between MAFLD with increased non-invasive fibrosis scores and risk of COVID-19 severity [5]. Patients with viral hepatitis, excessive alcohol consumption, active cancers or chronic pulmonary diseases were excluded. Clinical and laboratory data were collected in all patients at hospital admission, including NLR that was calculated by dividing the absolute number of neutrophils by the absolute number of lymphocytes. Obesity was diagnosed as body mass index >25 kg/m2. Pre-existing diabetes was defined as self-reported history of disease or use of glucose-lowering medications. All patients were screened for hepatic steatosis by computed tomography and subsequently diagnosed as MAFLD, according to the recently proposed diagnostic criteria [2]. The severity of COVID-19 was assessed during hospitalization and classified as severe and non-severe based on the current management guideline [6]. The study protocol was approved by the local ethics committees of the four hospitals. The requirement for written informed consent was waived due to the retrospective and anonymous nature of the study design.
2020
COVID-19
Coronavirus disease 2019
MAFLD
Metabolic associated fatty liver disease
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1030374
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact